Pfizer And Astellas Ink Co-promotion Agreement For Hypertension And Cholesterol Combo Drug Caduet In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Pfizer and Astellas Pharma have signed a co-promotion agreement for combination drug, Caduet (amlodipine and atorvastatin) for local Japanese distribution to treat both hypertension and hypercholesterolemia, the first combination drug for the two treatments, the two companies announced Aug. 26
You may also be interested in...
Astellas Gears Up To Launch Caduet With Pfizer; Ramps Up Oncology Franchise With Seattle Genetics Agreement
Pfizer Japan and Tokyo-based Astellas announced Nov. 26 that that they will launch combo drug Caduet (amlodipine/atorvastatin) in Japan Dec. 2
Astellas Gears Up To Launch Caduet With Pfizer; Ramps Up Oncology Franchise With Seattle Genetics Agreement
Pfizer Japan and Tokyo-based Astellas announced Nov. 26 that that they will launch combo drug Caduet (amlodipine/atorvastatin) in Japan Dec. 2
Takeda Gets Second Chance With U.S. FDA Complete Response On Actos Combo Drug
Osaka-based Takeda Pharmaceutical stated this week that it has received a complete response letter from U.S. FDA; the American drug regulator stated in the letter that the NDA review for a fixed-dose alogliptin and Actos (pioglitazone) combo drug will depend on additional data from a cardiovascular safety study FDA requested for the company's alogliptin monotherapy NDA